Classical Complement Pathway Inhibitor [EPC]

321 reported adverse events

Drugs of this class: SUTIMLIMAB-JOME

These side effects are most commonly reported by patients taking drugs of the Classical Complement Pathway Inhibitor [EPC] class:

# Side effect Count
0 OFF LABEL USE 39
1 HAEMOGLOBIN DECREASED 23
2 ARTHRALGIA 20
3 FATIGUE 18
4 DEATH 16
5 HAEMOLYSIS 16
6 CONDITION AGGRAVATED 15
7 DRUG INEFFECTIVE 13
8 HEADACHE 13
9 COVID-19 12
See all common reactions for Classical Complement Pathway Inhibitor [EPC]

Drugs of the Classical Complement Pathway Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 B-CELL MALIGNANCY 1 0.5000
1 CELLULITIS PASTEURELLA 1 0.2500
2 DEVICE MATERIAL OPACIFICATION 1 0.0222
3 BURSA INJURY 1 0.0154
4 DISSEMINATED VARICELLA ZOSTER VIRUS INFECTION 4 0.0110
5 COLD TYPE HAEMOLYTIC ANAEMIA 2 0.0085
6 HEPATITIS VIRAL 4 0.0050
7 AUTOANTIBODY POSITIVE 1 0.0036
8 INFECTION REACTIVATION 4 0.0035
9 BLOOD IMMUNOGLOBULIN M INCREASED 2 0.0033
See all enriched reactions for Classical Complement Pathway Inhibitor [EPC]